- Home
- KF vs ADAG Comparison
KF vs ADAG Comparison
Compare KF & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- ADAG
- Stock Information
- Founded
- KF 1984
- ADAG 2011
- Country
- KF United States
- ADAG China
- Employees
- KF N/A
- ADAG N/A
- Industry
- KF Investment Managers
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- KF Finance
- ADAG Health Care
- Exchange
- KF Nasdaq
- ADAG Nasdaq
- Market Cap
- KF 116.7M
- ADAG 110.8M
- IPO Year
- KF N/A
- ADAG 2021
- Fundamental
- Price
- KF $28.20
- ADAG $2.32
- Analyst Decision
- KF
- ADAG Strong Buy
- Analyst Count
- KF 0
- ADAG 2
- Target Price
- KF N/A
- ADAG $7.00
- AVG Volume (30 Days)
- KF 18.4K
- ADAG 111.5K
- Earning Date
- KF 01-01-0001
- ADAG 08-12-2025
- Dividend Yield
- KF N/A
- ADAG N/A
- EPS Growth
- KF N/A
- ADAG N/A
- EPS
- KF N/A
- ADAG N/A
- Revenue
- KF N/A
- ADAG $103,204.00
- Revenue This Year
- KF N/A
- ADAG $9,789.15
- Revenue Next Year
- KF N/A
- ADAG $29.92
- P/E Ratio
- KF N/A
- ADAG N/A
- Revenue Growth
- KF N/A
- ADAG N/A
- 52 Week Low
- KF $18.30
- ADAG $1.33
- 52 Week High
- KF $25.56
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- KF 59.50
- ADAG 57.48
- Support Level
- KF $26.79
- ADAG $2.11
- Resistance Level
- KF $27.83
- ADAG $2.45
- Average True Range (ATR)
- KF 0.34
- ADAG 0.19
- MACD
- KF 0.02
- ADAG 0.00
- Stochastic Oscillator
- KF 100.00
- ADAG 62.15
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.